APA (7th ed.) Citation

Modest, D., Heinemann, V., Schütt, P., Angermeier, S., Haberkorn, M., Waidmann, O., . . . Oettle, H. (2022). 1301P Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116). Annals of Oncology, 33, S1139. https://doi.org/10.1016/j.annonc.2022.07.1433

Chicago Style (17th ed.) Citation

Modest, D.P, et al. "1301P Sequential Therapy of Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After Failure of Gemcitabine Plus Nab-paclitaxel with Either 5-FU/folinic Acid (5FU/LV) Plus Irinotecan (FOLFIRI) Followed by 5FU/LV Plus Oxaliplatin (OFF) or the Reverse Sequence: The PANTHEON Trial (AIO PAK 0116)." Annals of Oncology 33 (2022): S1139. https://doi.org/10.1016/j.annonc.2022.07.1433.

MLA (9th ed.) Citation

Modest, D.P, et al. "1301P Sequential Therapy of Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After Failure of Gemcitabine Plus Nab-paclitaxel with Either 5-FU/folinic Acid (5FU/LV) Plus Irinotecan (FOLFIRI) Followed by 5FU/LV Plus Oxaliplatin (OFF) or the Reverse Sequence: The PANTHEON Trial (AIO PAK 0116)." Annals of Oncology, vol. 33, 2022, p. S1139, https://doi.org/10.1016/j.annonc.2022.07.1433.